Eris Lifesciences Limited share price
NSE: ERIS · ISIN INE406M01024
Key numbers
- Market cap
- ₹ 17,466 Cr
- Current price
- ₹ 1,258.90
- 52-week high / low
- ₹ 1,740 / 1,200
- Stock P/E
- 26.9
- Book value
- ₹ 285.5
- Dividend yield
- 1.15%
- ROCE
- 14.3%
- ROE
- 18.3%
- Debt to equity
- 0.60
- Sales growth (3 yrs)
- 23.3%
- Profit growth (3 yrs)
- 17.5%
- 1-year return
- -23.3%
About Eris Lifesciences Limited
Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally. The company offers various branded formulations in various therapeutic areas, such as antidiabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women's health, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electrocardiogram measurement, continuous glucose monitoring system, sleep study, and anti-natal care solutions. It offers its products through wholesale drug distributors, stockists, retail and e-commerce pharmacies. Eris Lifesciences Limited was incorporated in 2007 and is headquartered in Ahmedabad, India.
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 772 | 790 | 801 | 752 | 869 |
| Operating profit | 277 | 288 | 282 | 274 | 296 |
| Net profit | 118 | 120 | 100 | 282 | 142 |
| EPS (₹) | 8.66 | 8.82 | 7.32 | 20.60 | 10.28 |
Investor presentation summary (2026-07-29)
AI summary of the presentation · tone: Positive · source document
Key numbers
- DBF Q1 Revenue up 14.2% YoY with a Consol. PAT growth of 14.5% YoY
- Organic revenue growth of 13% with a PAT growth of 14.5%
Guidance & outlook
- Financial highlights - Q1 FY27
- Organic growth of 14% in Q1 FY27 with a 35% EBIDTA Margin
Growth & demand
- DBF - Q1 organic growth 14.2%
- Broad-based growth momentum with the two largest therapies, OAD and Cardiac (35% of portfolio) yet to achieve full momentum
Margins & costs
- (~14%) - a function of more accessible pricing
- margin contraction in FY27,
Capex & expansion
- RHI and Glargine – Market share increased from 9% to 16% since Biocon acquisition
- The ability to successfully implement our strategy, our research and development efforts, growth & expansion plans and technological changes;
Peers in Drug Manufacturers - Specialty & Generic
Data for information only, not investment advice. Prices end of day.